Drug Information

Drug (ID: DG00695) and It's Reported Resistant Information

• Name: Tacrine
• Synonyms: Tacrine; 1,2,3,4-tetrahydroacridin-9-amine; 321-64-2; Tetrahydroaminacrine; 1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE; Tetrahydroaminoacridine; Tetrahydroaminocrine; Cognex; Tetrahydroaminocrin; 9-amino-1,2,3,4-tetrahydroacridine; Tacrinum; 9-Acridinamine, 1,2,3,4-tetrahydro-; CS 12602; UNII-4VX7YNB537; 1,2,3,4-Tetrahydro-9-aminoacridine; Acridine, 1,2,3,4-tetrahydro-9-amino-; CHEMBL95; 5-Amino-6,7,8,9-tetrahydroacridine; 4VX7YNB537; CHEBI:45980; 5,6,7,8-tetrahydroacridin-9-amine; tacrine.HCl; NCGC00015054-06; Tacrina; Tacrine [INN:BAN]; Tacrinum [INN-Latin]; Tacrina [INN-Spanish]; DSSTox_CID_17272; DSSTox_RID_79318; DSSTox_GSID_37272; Tacrinal; Tacrinal (TN); CAS-321-64-2; Tacrine (INN); EINECS 206-291-2; 5-Amino-6,7,8,9-tetrahydroacridine (European); BRN 0147610; 1,2,3,4-Tetrahydro-acridin-9-ylamine; Tracine; 1acj; 2aow; 2aox; 1,2,3,4-Tetrahydro-9-acridineamine; Romotal (Salt/Mix); Spectrum_000416; Tocris-0965; 1mx1; Prestwick0_000329; Prestwick1_000329; Prestwick2_000329; Prestwick3_000329; Spectrum2_001812; Spectrum3_001709; Spectrum4_000819; Spectrum5_001402; Lopac-A-3773; cid_1935; SCHEMBL2828; 9-THA; NCIOpen2_003667; Lopac0_000036; Oprea1_008681; Acridine, 9-aminotetrahydro-; BSPBio_000337; BSPBio_003298; KBioGR_001337; KBioSS_000896; BIDD:GT0090; DivK1c_000936; SPBio_001823; SPBio_002258; BDBM8961; BPBio1_000371; GTPL6687; DTXSID1037272; KBio1_000936; KBio2_000896; KBio2_003464; KBio2_006032; KBio3_002518; NINDS_000936; HMS2089F19; HMS3743C11; BCP03564; Tox21_110073; Tox21_302277; MFCD00046923; PDSP1_000330; PDSP2_000328; STK101308; ZINC19014866; AKOS000277493; Tox21_110073_1; BCP9000019; CCG-204132; DB00382; MCULE-3628803328; SDCCGSBI-0050025.P004; 1,2,3,4-tetra -hydro-9-acridinamine; IDI1_000936; NCGC00015054-01; NCGC00015054-02; NCGC00015054-03; NCGC00015054-04; NCGC00015054-05; NCGC00015054-07; NCGC00015054-08; NCGC00015054-09; NCGC00015054-10; NCGC00015054-12; NCGC00024908-01; NCGC00024908-03; NCGC00024908-04; NCGC00024908-05; NCGC00255540-01; 1,2,3,4-tetrahydro-acridin-9-yl-amine; BS-28027; Acridine, 9-amino-1,2,3,4-tetrahydro-; SBI-0050025.P003; DB-000650; 9-amino-1,2,3,4-tetrahydroacridine (THA); AB00053524; C-110; EU-0010966; FT-0631953; 9-Acridinamine, 1,2,3,4-tetrahydro- (9CI); A18628; C01453; D08555; AB00053524-17; AB00053524_18; AB00053524_19; AE-641/00604043; Q421076; BRD-K81473089-003-03-0; BRD-K81473089-003-04-8; BRD-K81473089-003-15-4; SR-01000075593-13; Z56790573
• Indication:
  In total 1 Indication(s)
  Alzheimer disease [ICD-11: 8A20]; Approved; [1]
• Target: Acetylcholinesterase (AChE); ACES_HUMAN; [1]
• Formula: C13H14N2
• IsoSMILES: C1CCC2=NC3=CC=CC=C3C(=C2C1)N
• InChI: 1S/C13H14N2/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13/h1,3,5,7H,2,4,6,8H2,(H2,14,15)
• InChIKey: YLJREFDVOIBQDA-UHFFFAOYSA-N
• PubChem CID: 1935
• ChEBI ID: CHEBI:45980
• TTD Drug ID: D0E6YQ
• VARIDT ID: DR00183
• DrugBank ID: DB00382

Type(s) of Resistant Mechanism of This Drug

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-08: Nervous system diseases

Alzheimer's disease [ICD-11: 8A20]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: Amyloid-beta precursor protein (APP) [1]

• Sensitive Disease: Alzheimer's disease [ICD-11: 8A20.0]
• Molecule Alteration: Expression; Up-regulation
• Experimental Note: Identified from the Human Clinical Data
• Mechanism Description: By using tacrine to target the active catalytic site (CAS), the tacrine-based MTDLs can act on both CAS and peripheral anion site (PAS) of AChE to serve as a dual-site AChE inhibitor. Additionally, the tacrine-based MTDLs can also be designed on the basis of other theories of AD, for example, introducing functional moieties to modulate the formation of beta-amyloid (Abeta), oxidation resistance, or metal chelation.

References

• Ref 1: Multi-Target Drug Design of Anti-Alzheimer's Disease based on Tacrine .Mini Rev Med Chem. 2021;21(15):2039-2064. doi: 10.2174/1389557521666210212151127. 10.2174/1389557521666210212151127